Publicacións en colaboración con investigadores/as de Instituto de Salud Carlos III (29)

2024

  1. Circulating biomarkers of myocardial remodelling: current developments and clinical applications

    Heart, Vol. 110, Núm. 19, pp. 1157-1163

  2. Myocardial Interstitial Fibrosis in Hypertensive Heart Disease: From Mechanisms to Clinical Management

    Hypertension, Vol. 81, Núm. 2, pp. 218-228

2022

  1. A Fibrosis Biomarker Early Predicts Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy

    Cancers, Vol. 14, Núm. 12

  2. ADAMTSL3 knock-out mice develop cardiac dysfunction and dilatation with increased TGFβ signalling after pressure overload

    Communications Biology, Vol. 5, Núm. 1

  3. Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial

    European Journal of Heart Failure, Vol. 24, Núm. 2, pp. 321-331

  4. Heart failure in chronic kidney disease: The emerging role of myocardial fibrosis

    Nephrology Dialysis Transplantation, Vol. 37, Núm. 5, pp. 817-824

2021

  1. Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches

    Nature Reviews Cardiology, Vol. 18, Núm. 7, pp. 479-498

2020

  1. Burden and challenges of heart failure in patients with chronic kidney disease. A call to action

    Nefrologia, Vol. 40, Núm. 3, pp. 223-236

  2. Cardiac magnetic resonance-derived fibrosis, strain and molecular biomarkers of fibrosis in hypertensive heart disease

    Journal of hypertension, Vol. 38, Núm. 10, pp. 2036-2042

  3. Cardiorenal interaction and heart failure outcomes. A role for insulin-like growth factor binding protein 2?

    Revista Espanola de Cardiologia, Vol. 73, Núm. 10, pp. 835-843

  4. H3K27ac acetylome signatures reveal the epigenomic reorganization in remodeled non-failing human hearts

    Clinical Epigenetics, Vol. 12, Núm. 1

  5. Hypertrophic cardiomyopathy in myosin-binding protein C (MYBPC3) Icelandic founder mutation carriers

    Open Heart, Vol. 7, Núm. 1

  6. Natural Compound Library Screening Identifies New Molecules for the Treatment of Cardiac Fibrosis and Diastolic Dysfunction

    Circulation, Vol. 141, Núm. 9, pp. 751-767

  7. Reprint of “The complex dynamics of myocardial interstitial fibrosis in heart failure. Focus on collagen cross-linking”

    Biochimica et Biophysica Acta - Molecular Cell Research, Vol. 1867, Núm. 3

2019

  1. Association of left atrium voltage amplitude and distribution with the risk of atrial fibrillation recurrence and evolution after pulmonary vein isolation: An ultrahigh-density mapping study

    Journal of Cardiovascular Electrophysiology, Vol. 30, Núm. 8, pp. 1231-1240

  2. CT-1 (Cardiotrophin-1)-Gal-3 (Galectin-3) axis in cardiac fibrosis and inflammation: Mechanistic insights and clinical implications

    Hypertension, Vol. 73, Núm. 3, pp. 602-611

  3. Circulating biomarkers predicting longitudinal changes in left ventricular structure and function in a general population

    Journal of the American Heart Association, Vol. 8, Núm. 2

  4. Circulating long noncoding RNA LIPCAR Predicts heart failure outcomes in patients without chronic kidney disease

    Hypertension, Vol. 73, Núm. 4, pp. 820-828

  5. Combination of Circulating Type I Collagen-Related Biomarkers Is Associated With Atrial Fibrillation

    Journal of the American College of Cardiology, Vol. 73, Núm. 12, pp. 1398-1410

  6. Increased Fibroblast Growth Factor 23 in Heart Failure: Biomarker, Mechanism, or Both?

    American Journal of Hypertension